Cleared Traditional

AXIS %CDT TURBIDIMETRIC IMMUNOASSAY (K992502) - FDA 510(k) Clearance

Class I Chemistry device.

K992502 · Axis · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1999
Decision
148d
Days
Class 1
Risk

K992502 is an FDA 510(k) clearance for the AXIS %CDT TURBIDIMETRIC IMMUNOASSAY. Classified as Test, Carbohydrate Deficient Transferrin (product code NAO), Class I - General Controls.

Submitted by Axis (San Diego, US). The FDA issued a Cleared decision on December 21, 1999 after a review of 148 days - within the typical 510(k) review window.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1360 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all Axis devices

Submission Details

510(k) Number K992502 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 26, 1999
Decision Date December 21, 1999
Days to Decision 148 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
60d slower than avg
Panel avg: 88d · This submission: 148d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code NAO Test, Carbohydrate Deficient Transferrin
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1360
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.